Jointown Pharmaceutical Group
Launch date
Market cap
$3.1b
Enterprise valuation
$3.2b (Public information from Sep 2024)
Share price
CNY4.5 600998.SS
Wuhan Hubei (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 110.9b | 122.4b | 140.4b | 150.1b | 157.7b | 185.0b | 208.9b |
| % growth | 11 % | 10 % | 15 % | 7 % | 5 % | 17 % | 13 % |
| EBITDA | 4.7b | 4.1b | 5.1b | 5.4b | 5.0b | 6.0b | 7.1b |
| % EBITDA margin | 4 % | 3 % | 4 % | 4 % | 3 % | 3 % | 3 % |
| Profit | 3.1b | 2.4b | 2.1b | 2.2b | 2.4b | 3.1b | 3.8b |
| % profit margin | 3 % | 2 % | 1 % | 1 % | 2 % | 2 % | 2 % |
| EV / revenue | 0.3x | 0.2x | 0.2x | 0.2x | 0.1x | 0.1x | 0.1x |
| EV / EBITDA | 7.6x | 7.1x | 4.3x | 4.5x | 4.0x | 3.4x | 2.7x |
| R&D budget | 127m | 195m | 178m | 197m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
